Metagenomi Therapeutics, Inc. (MGX)
0.92
-0.10
(-9.80%)
USD |
NASDAQ |
Oct 13, 14:53
Metagenomi Therapeutics Total Assets (Quarterly) : 173.70M for June 30, 2026
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 173.70M |
| March 31, 2026 | 196.95M |
| December 31, 2025 | 233.28M |
| September 30, 2025 | 247.94M |
| June 30, 2025 | 272.28M |
| March 31, 2025 | 297.87M |
| December 31, 2024 | 324.60M |
| September 30, 2024 | 358.35M |
| Date | Value |
|---|---|
| June 30, 2024 | 385.90M |
| March 31, 2024 | 415.40M |
| December 31, 2023 | 364.84M |
| September 30, 2023 | 386.43M |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | 414.49M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Assets (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 2.112B |
| Oncolytics Biotech, Inc. | 7.671M |
| Sangamo Therapeutics, Inc. | 59.96M |
| Sarepta Therapeutics, Inc. | 3.189B |
| Anixa Biosciences, Inc. | 15.07M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 61.13M |
| Shareholders Equity (Quarterly) | 112.57M |
| Debt to Equity Ratio | 0.3351 |
| Current Ratio | 4.504 |
| Net Debt Paydown Yield | 2.99% |